BioPharm International
August 01, 2017
Regulatory Beat
30
8
FDA urges manufacturers to seek fast approval of “high-need” generics and targeted therapies.
August 01, 2017
Perspectives on Outsourcing
30
8
Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.
August 01, 2017
From the Editor
30
8
Amid debate about “fake news,” peer-review papers offer vital, objective insight.
August 01, 2017
Cover Story
30
8
Improved resin chemistries and customized separation solutions are enabling more efficient separations.
August 01, 2017
Features
30
8
Media manufacturers are focused on reducing risk, improving quality and consistency, and managing costs.
August 01, 2017
Features
30
8
Industry experts weigh in on best practices, challenges, and mutual recognition of cleaning validation standards.
August 01, 2017
Features
30
8
Managing and prioritizing risk is essential to ensuring raw material quality. USP is developing new guidelines to make the work easier.
August 01, 2017
Features
30
8
Investigational failures and discrepancies can be avoided through the proper execution and documentation of investigations.
August 01, 2017
Features
30
8
The author outlines an analytical strategy for establishing similarity in biosimilar development and approval.
August 01, 2017
Issue PDF
30
8
Click the title above to open the BioPharm International August 2017 issue in an interactive PDF format.